Paper12960733
Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
van Kesteren Ch and 6 others. Anticancer Drugs, 2003. Cited by 65 papers, by iCite.
Cite this record
ConductScience Library. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin. Papers, record 12960733. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12960733
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Alkylating | Major topic |
| Dioxoles | Major topic |
| Isoquinolines | Major topic |
| Neoplasms | Major topic |
| Animals | |
| Cell Cycle | |
| Chemistry, Pharmaceutical | |
| Clinical Trials as Topic | |
| Female | |
| Humans | |
| Tetrahydroisoquinolines | |
| Trabectedin |
Source PubMed
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 65 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42356528 | Natural Products as Promising Pharmacological Agents Against Cancer: A Holistic Overview of Their Anti-Cancer Mechanisms of Action of the Last Five Years. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42356528 | PubMed |
| 41745729 | The Cardioprotective Potential of Marine Venom and Toxins. | Toxins (Basel) | 2026 | https://conductscience.org/library/papers/41745729 | PubMed |
| 39797969 | Didemnins as marine-derived anticancer agents: mechanistic insights and clinical potential. | Med Oncol | 2025 | https://conductscience.org/library/papers/39797969 | PubMed |
| 39450552 | Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review). | Int J Mol Med | 2025 | https://conductscience.org/library/papers/39450552 | PubMed |
| 39228518 | Radiological evaluation of response in patients with locally advanced/metastatic soft tissue sarcoma treated with trabectedin. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39228518 | PubMed |
| 32500752 | PXR-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches. | Expert Opin Drug Metab Toxicol | 2020 | https://conductscience.org/library/papers/32500752 | PubMed |
| 31782213 | Strategies for developing pregnane X receptor antagonists: Implications from metabolism to cancer. | Med Res Rev | 2020 | https://conductscience.org/library/papers/31782213 | PubMed |
| 31621891 | Enriching cancer pharmacology with drugs of marine origin. | Br J Pharmacol | 2020 | https://conductscience.org/library/papers/31621891 | PubMed |
| 31482373 | Radiosensitizing effects of trabectedin on human A549 lung cancer cells and HT-29 colon cancer cells. | Invest New Drugs | 2020 | https://conductscience.org/library/papers/31482373 | PubMed |
| 31208455 | An appraisal of natural products active against parasitic nematodes of animals. | Parasit Vectors | 2019 | https://conductscience.org/library/papers/31208455 | PubMed |
| 30366467 | Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line. | Cells | 2018 | https://conductscience.org/library/papers/30366467 | PubMed |
| 29449896 | Myxofibrosarcoma primary cultures: molecular and pharmacological profile. | Ther Adv Med Oncol | 2017 | https://conductscience.org/library/papers/29449896 | PubMed |
| 29292724 | Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents. | Int J Mol Sci | 2017 | https://conductscience.org/library/papers/29292724 | PubMed |
| 28794805 | Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. | Ther Adv Med Oncol | 2017 | https://conductscience.org/library/papers/28794805 | PubMed |
| 27541923 | Clinical Implications of Sarcopenic Obesity in Cancer. | Curr Oncol Rep | 2016 | https://conductscience.org/library/papers/27541923 | PubMed |
| 26921498 | Small-molecule modulators of PXR and CAR. | Biochim Biophys Acta | 2016 | https://conductscience.org/library/papers/26921498 | PubMed |
| 25614221 | The re-emergence of natural products for drug discovery in the genomics era. | Nat Rev Drug Discov | 2015 | https://conductscience.org/library/papers/25614221 | PubMed |
| 25252616 | Pregnane X receptor and drug-induced liver injury. | Expert Opin Drug Metab Toxicol | 2014 | https://conductscience.org/library/papers/25252616 | PubMed |
| 21523334 | Emerging therapeutic targets for soft tissue sarcoma. | Curr Oncol Rep | 2011 | https://conductscience.org/library/papers/21523334 | PubMed |
| 19238326 | Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice. | Invest New Drugs | 2010 | https://conductscience.org/library/papers/19238326 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/12960733
GET https://conductscience.org/api/papers/v1/12960733/cited_by?page=2